Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
21.01
+0.36 (1.74%)
At close: Nov 18, 2026, 4:00 PM EST
21.49
+0.48 (2.28%)
After-hours: Nov 18, 2026, 7:45 PM EST
Beam Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Beam Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $49.85. The average 1-year stock price forecast is 137.27% higher than the current stock price, while the lowest is $26 (+23.75%) and the highest is $80 (+280.77%).
Price Target: $49.85 (+137.27%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Beam Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 12 | 12 | 12 | 12 | 12 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $78 | Buy | Reiterates | $78 | +271.25% | Nov 11, 2026 |
| Citi | Citi | Buy Reiterates $64 → $68 | Buy | Reiterates | $64 → $68 | +223.66% | Nov 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $80 | Buy | Reiterates | $80 | +280.77% | Nov 10, 2026 |
| Wedbush | Wedbush | Buy Maintains $30 → $33 | Buy | Maintains | $30 → $33 | +57.07% | Nov 10, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $55 → $51 | Buy | Maintains | $55 → $51 | +142.74% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
38.48M
from 139.74M
Decreased by -72.46%
Revenue Next Year
27.53M
from 38.48M
Decreased by -28.45%
EPS This Year
-4.55
from -0.81
EPS Next Year
-5.05
from -4.55
EPS and Forward PE are based on non-GAAP adjusted numbers.